Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants

Psychosomatic Medicine

Volumn 61, Issue 5, 1999, Pages 599-617

  Chen, Guang ^a   Hasanat, Khondakar A ^a   Bebchuk, Joseph M ^a   Moore, Gregory J ^a   Glitz, Debra ^a   Manji, Husseini K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Gene expression; Lithium; Mood disorders; Protein kinase C; Valproate

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIC AMP; LITHIUM; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID;

AFFECTIVE NEUROSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

EID: 0032830190     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199909000-00004     Document Type: Article

References (170)

1. Bourne HR, Nicoll R. Molecular machines integrate coincident synaptic signals. Cell 1993;72(Suppl):65-75.
2. Ross EM. Signal sorting and amplification through G protein-coupled receptors. Neuron 1989;3:141-52.
3. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992;149:746-60.
4. Spiegel AM, editor. G proteins, receptors, and disease. Totowa (NJ): Humana Press; 1998.
5. Weinstein LS. Alteration of G protein expression or function in pathophysiology. In: Spiegel AM, Jones TLZ, Simonds WF, Weinstein LS, editors. G proteins. Austin (TX): RG Landes; 1994. p. 118-28.
6. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993;13:278-93.
7. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994;77:429-41.
8. Wang JF, Young LT, Li PP, Warsh JJ. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical applications. New York: Marcel Dekker; 1997. p. 41-79.
9. Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science 1991;252:802-8.
10. Potter WZ, Manji HK. Affective disorders and adrenergic function: an update. Clin Biochem 1994;40:279-87.
11. Siever LJ, Uhde TW, Jimerson DC, Lake CR, Siberman ER, Post RM, Murphy DL. Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am J Psychiatry 1984;141:733-41.
12. 2-adrenergic receptors in depression. Arch Gen Psychiatry 1986;43:91-5.
13. Charney DS, Heninger GR, Sternberg DE, Hafstad KM, Giddings S, Landis DH. Adrenergic receptor sensitivity in depression: effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 1982;39:290-4.
14. Siever LJ. Role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 493-504.
15. 2-adrenoreceptors in depression: a critical examination. J Psychopharmacol 1993; 7:4-18.
16. Pandey GN, Dysken MW, Garver DL, Davis JM. Beta-adrenergic receptor function in affective illness. Am J Psychiatry 1979; 136:675-8.
17. Extein I, Tallman J, Smith CC, Goodwin FK. Changes in lymphocyte β-adrenergic receptors in depression and mania. Psychiatry Res 1979;1:191-7.
18. Mann JJ, Brown RP, Halper JP, Sweeney JA, Kocsis JH, Stokes PE, Bilezikian JP. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985;313:715-20.
19. Healy D, Carney PA, Leonard BE. Monoamine-related markers of depression: changes following treatment. J Psychiatr Res 1983;17:251-60.
20. Ebstein RP, Lerer B, Shapira B, Shemesh Z, Moscovich DG, Kindler S. Cyclic AMP second-messenger signal amplification in depression. Br J Psychiatry 1988;152:665-9.
21. Halper JP, Brown RP, Sweeney JA, Kocsis JH, Peters A, Mann JJ. Blunted beta-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression: isoproterenol dose-response studies. Arch Gen Psychiatry 1988;45:241-4.
22. Wright AF, Crichton DN, Loudon JP, Morten JE, Steel CM. Beta-adrenoceptor binding defects in cell lines from families with manic-depressive disorder. Ann Hum Genet 1984;48(Pt 3):201-14.
23. Ebstein R, Oppenheim G, Ebstein BS, Amiri Z, Stessman J. The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:323-53.
24. Berrettini WH, Bardakjian J, Cappellari CB, Barnett AL Jr, Albright A, Nurnberger JI Jr, Gershon ES. Skin fibroblast beta-adrenergic receptor function in manic-depressive illness. Biol Psychiatry 1987;22:1439-43.
25. Berrettini WH, Cappellari CB, Nurnberger JI Jr, Gershon ES. Beta-adrenergic receptors on lymphoblasts: a study of manic-depressive illness. Neuropsychobiology 1987;17:15-8.
26. s α protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993;61:890-8.
27. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996;40:568-75.
28. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A, Guimon J. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999;72:282-91.
29. Schreiber G, Avissar S, Danon A, Belmaker RH. Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry 1991;29:273-80.
30. Young LT, Li PP, Kamble A, Siu KP, Warsh JJ. Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder. Am J Psychiatry 1994;151:594-6.
31. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder: effects of long-term lithium treatment. Arch Gen Psychiatry 1995;52:135-44.
32. Spleiss O, van Calker D, Scharer L, Adamovic K, Berger M, Gebicke-Haerter PJ. Abnormal G protein alpha(s)- and alpha(i2)-subunit mRNA expression in bipolar affective disorder. Mol Psychiatry 1998;3:512-20.
33. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Am J Psychiatry 1997; 154:211-7.
34. Garcia-Sevilla JA, Walzer C, Busquets X, Escriba PV, Balant L, Guimon J. Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biol Psychiatry 1997;42:704-12.
35. Mooney JJ, Samson JA, McHale NL, Colodzin R, Alpert J, Koutsos M, Schildkraut JJ. Signal transduction by platelet adenylate cyclase: alterations in depressed patients may reflect impairment in the coordinated integration of cellular signals (coincidence detection). Biol Psychiatry 1998;43:574-83.
36. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression. Am J Psychiatry 1998;155:666-71.
37. Karege F, Bovier P, Stepanian R, Malafosse A. The effect of clinical outcome on platelet G proteins of major depressed patients. Eur Neuropsychopharmacol 1998;8:89-94.
38. Ram A, Guedj F, Cravchik A, Weinstein L, Cao Q, Badner J, Goldin LR, Grisaru N, Manji HK, Belmaker RH, Gershon ES, Gejman PV. No abnormality in the gene for the G protein stimulatory α subunit in patients with bipolar disorder. Arch Gen Psychiatry 1997;54:44-8.
39. Brown AS, Mallinger AG, Renbaum LC. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania. Am J Psychiatry 1993;150:1252-4.
40. Soares JC, Dippold CS, Mallinger AG. Platelet membrane phosphatidylinositol-4,5-bisphosphate alterations in bipolar disorder - evidence from a single case study. Psychiatry Res 1997; 69:197-202.
41. 2+ response in neutrophils of manic-depressive patients: effect of lithium therapy. Neuropsychobiology 1993; 27:180-3.
42. Pandey SC, Davis JM, Schwertz DW, Pandey GN. Effect of antidepressants and neuroleptics on phosphoinositide metabolism in human platelets. J Pharmacol Exp Ther 1991;256: 1010-8.
43. Pandey GN, Pnadey SC, Davis JM. Effects of desipramine on inositol phosphate formation and inositol phospholipids in rat brain and human platelets. Psychopharmacol Bull 1991;27: 255-61.
44. Li R, Wing LL, Wyatt RD, Kirch DG. Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain. Pharmacol Biochem Behav 1993;46:323-9.
45. Mathews R, Li PP, Young LT, Kish SJ, Warsh JJ. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol Psychiatry 1997;41:649-56.
46. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, Warsh JJ. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 1996; 66:2402-9.
47. Freidman E, Hoau YW, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993;33:520-5.
48. Pandey GN, Dwivedi Y, Pandey SC, Conley RR, Roberts RC, Tamminga CA. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997;228:111-4.
49. Sulser F. Antidepressant treatments and regulation of norepinephrine-receptor-coupled adenylate cyclase systems in brain. Adv Biochem Psychopharmacol 1984;39:249-61.
50. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5: 219-24.
51. Okada F, Tokumitsu Y, Ui M. Desensitization of beta-adrenergic receptor-coupled adenylate cyclase in cerebral cortex after in vivo treatment of rats with desipramine. J Neurochem 1986;47:454-9.
52. Tiong AH, Richardson JS. Beta-adrenoceptor and post-receptor components show different rates of desensitization to desipramine. Eur J Pharmacol 1990;188:411-5.
53. Tsuchiya F, Ikeda H, Hatta Y, Saito T. Effects of desipramine administration on receptor adenylate cyclase coupling in rat cerebral cortex. Jpn J Psychiatr Neurol 1988;42:858-60.
54. Yamaoka K, Nanba T, Nomura S. Direct influence of antidepressants on GTP binding protein of adenylate cyclase in cell membranes of the cerebral cortex of rats. J Neural Transm 1988;71:165-75.
55. Okada F, Tokumitsu Y, Ui M. Possible involvement of pertussis toxin substrates (Gi, Go) in desipramine-induced refractoriness of adenylate cyclase in cerebral cortices of rats. J Neurochem 1988;51:194-9.
56. Simonds WF, Manji HK, Lupas A, Garritsen A. G proteins and βARK: a new twist for the coiled-coil. Trends Biochem Sci 1993;18:315-7.
57. Lesch KP, Manji HK. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry 1992;32:549-79.
58. Raap DK, Evans S, Garcia F, Li Q, Muma NA, Wolf WA, Battaglia G, Van De Kar LD. Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther 1999;288:98-106.
59. Dwivedi Y, Pandey GN. Effects of subchronic administration of antidepressants and anxiolytics on levels of the alpha subunits of G proteins in the rat brain. J Neural Transm 1997;104: 747-60.
60. Li Q, Muma NA, Battaglia G, Van de Kar LD. A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. J Pharmacol Exp Ther 1997;282:1581-90.
61. Li Q, Muma NA, van de Kar LD. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J Pharmacol Exp Ther 1996;279:1035-42.
62. Emamghoreishi M, Warsh JJ, Sibony D, Li PP. Lack of effect of chronic antidepressant treatment on Gs and Gi alpha-subunit protein and mRNA levels in the rat cerebral cortex. Neuropsychopharmacology 1996;15:281-7.
63. McGowan S, Eastwood SL, Mead A, Burnet PW, Smith C, Flanigan TP, Harrison PJ. Hippocampal and cortical G protein (Gs alpha, G(o) alpha and Gi2 alpha) mRNA expression after electroconvulsive shock or lithium carbonate treatment. Eur J Pharmacol 1996;306:249-55.
64. Rasenick MM, Chaney KA, Chen J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. J Clin Psychiatry 1996; 57(Suppl 13):49-55.
65. Lason W, Przewlocki R. The effect of chronic treatment with imipramine on the G proteins mRNA level in the rat hippocampus - an interaction with a calcium channel antagonist. Pol J Pharmacol 1993:45:219-26.
66. Sugrue MF. Chronic antidepressant therapy and associated changes in central monoaminergic function. Pharmacol Ther 1983;21:1-37.
67. Newman ME, Lerer B, Lichtenberg P, Shapira B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment. Psychopharmacology 1992;109:231-4.
68. Chen J, Rasenick MM. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther 1995:275:509-17.
69. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science 1983;219:65-7.
70. Ozawa H, Rasenick MM. Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Mol Pharmacol 1989;36:803-8.
71. Newman ME, Lerer B. Post-receptor-mediated increases in adenylate cyclase activity after chronic ad treatment: relationship to receptor desensitization. Eur J Pharmacol 1989;162:345-52.
72. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989;53:1644-7.
73. Perez J, Tinelli D, Brunello N, Racagni G. cAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol 1989;172:305-16.
74. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
75. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression cAMP response elementbinding protein (CREB) in rat hippocampus. J Neurosci 1996; 16:2365-72.
76. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992;58:18-38.
77. Allison JH, Stewart MA. Reduced brain inositol in lithium treated rats. Nature 1971;233:267-8.
78. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980;255:10896-901.
79. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59: 411-9.
80. Jope RS Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999;4:117-28.
81. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-43.
82. Pontzer NJ, Crews FT. Desensitization of muscarinic stimulated hippocampal cell firing is related to phosphoinositide hydrolysis and inhibited by lithium. J Pharmacol Exp Ther 1990;253:921-9.
83. Kofman O, Belmaker RH. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993;34:839-52.
84. Godfrey PP, McClue SJ, White AM, Wood AJ, Grahame-Smith DG. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J 1989;258:621-4.
85. Tricklebank MD, Singh L, Jackson A, Oles RJ. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res 1991;558: 145-8.
86. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK. Temporal dissociation between lithium-induced CNS myo-inositol changes and clinical response in manic-depressive illness. AM J Psychiatry. In press 1999.
87. Lenox RH, Manji HK. Lithium. In: CB Nemeroff, AF Schatzberg, editors. American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington (DC): American Psychiatric Press; 1998. p. 379-430.
88. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258: 607-14.
89. Stabel S, Parker PJ. Protein kinase C. Pharmacol Ther 1991;51: 71-95.
90. Huang KP. The mechanism of protein kinase C activation. Trends Neurosci 1989;12:425-32.
91. Manji HK, Chen G, Risby ED, Masana MI, Hsiao JK, Potter WZ. Regulation of signal transduction pathways by mood stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996;57:34-46.
92. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology 1989;99:213-8.
93. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991;5:87-130.
94. Lenox RH, Watson DG, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570:333-40.
95. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996 7;767-77.
96. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in the hippocampus: selectivity for the alpha isozyme. J Neurochem 1993;61:2303-10.
97. Leli U, Hauser G. Lithium modifies diacylglycerol levels and protein kinase C in neuroblastoma cells. Abstracts of the 8th International Conference on Second Messengers and Phosphoproteins; 1992 October; abstract Z187F. Glasgow, Scotland
98. Li X, Jope RS. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells. J Neurochem 1995;65:2500-8.
99. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem 1994;63:2361-4.
100. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998;285:307-16.
101. Conn PJ, Sweatt JD. Protein kinase C in the nervous system. In: Kuo JF, editor. Protein kinase C. New York: Oxford University Press; 1994. p. 199-235.
102. Jordan VC. A current view of tamoxifen for the treatment of breast cancer. Br J Pharmacol 1994;110:507-17.
103. Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Saf 1993;8:381-97.
104. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo ML. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32: 485-9.
105. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Manji HK. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Arch Gen Psychiatry. In press.
106. Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992; 71(Suppl 1):4-17.
107. Risby ED, Hsiao JK, Manji HK, Bitran J, Moses F, Zhou DF, Potter WZ. The mechanisms of action of lithium. II. Effects of adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991;48:513-24.
108. Masana MI, Bitran JA, Hsiao JK, Mefford IN, Potter WZ. Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. Brain Res 1991;538:333-6.
109. Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999;4:21-5.
110. Andersen PH, Geisler A. Lithium inhibition of forskolin-stimulated adenylate cyclase. Neuropsychobiology 1984;12: 1-3.
111. Geisler A, Klysner R, Andersen PH. Influence of lithium in vitro and in vivo on the catecholamine-sensitive cerebral adenylate cyclase systems. Acta Pharmacol Toxicol (Copenh) 1985;56:80-97.
112. Mork A, Geisler A. Mode of action on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol 1987;60: 241-8.
113. Mork A, Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neuropharmacology 1989;28:307-11.
114. Newman ME, Belmaker RH. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987;26:211-7.
115. Newman ME, Shapira B, Lerer B. Effects of lithium and desimipramine on second messenger responses in rat hippocampus: relation to G protein effects. Neurpharmacology 1991;30:1297-301.
116. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification. Psychiatry Res 1987;21:221-8.
117. Casebolt TL, Jope RS. Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biol Psychiatry 1989;25:329-40.
118. Greenwood AF, Jope RS. Brain G-protein proteolysis by calpain: enhancement by lithium. Brain Res 1994;636:320-6.
119. Song L, Jope R. Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions. J Neurochem 1992;58:2200-6.
120. Li PP, Young LT, Tam YK, Sibony D, Warsh JJ. Effects of chronic lithium and carbamazepine treatment of G protein expression in rat cerebral cortex. Biol Psychiatry 1993;34: 162-70.
121. Masana MI, Bitran JA, Hsiao JK, Potter WZ. In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. J Neurochem 1992;59:200-5.
122. Colin SF, Chang HC, Mollner S, Pfeuffer T, Reed RR, Duman RS, Nestler EJ. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex. Proc Natl Acad Sci USA 1991;88:10634-7.
123. Jakobsen SN, Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res 1998;780:46-55.
124. Hsiao JK, Manji HK, Chen GA, Bitran JA, Risby ED, Potter WZ. Lithium administration modulates platelet Gi in humans. Life Sci 1992;50:227-33.
125. Lonati-Galligani M, Emrich HM, Raptis C, Pirke KM. Effect of in vivo lithium treatment on (-)isoproterenol-stimulated cAMP accumulation in lymphocytes of healthy subjects and patients with affective psychoses. Pharmacopsychiatry 1989;22:241-5.
126. Wang YC, Pandey GN, Mendels J, Frazer A. Effect of lithium on prostaglandin F1-stimulated adenylate cyclase activity of human platelets. Biochem Pharmacol 1974;23:845-55.
127. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder: effect of long-term lithium carbonate treatment. Arch Gen Psychiatry 1986;43:51-7.
128. Ui M. Pertussis toxin as a valuable probe for G protein involvement in signal transduction. In: Moss J, Vaughn M, editors. ADP-ribosylation toxins and G proteins. Washington (DC): American Society for Microbiology; 1990. p. 45-79
129. Manji HK, Bebchuk JM, Moore, GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood stabilizing agents: therapeutic implications. J Clin Psychiatry 1999;60(Suppl 2):27-39.
130. Kofman O, Li PP, Warsh JJ. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol Biochem Behav 1998;59:191-200.
131. Young LT, Woods CM. Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. Eur J Pharmacol 1996;309:215-8.
132. Nestler EJ, Terwilliger RZ, Duman RS. Regulation of endogenous ADP-ribosylation by acute and chronic lithium in rat brain. J Neurochem 1995;64:2319-24.
133. Chen G, Manji HK, Wright CB, Hawver D, Potter WZ. Effects of valproic acid on β-adrenergic receptors, G-proteins and adenylate-cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996;15:271-80.
134. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93: 8455-9.
135. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998;329(Pt 2):209-23.
136. Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 1998;8:95-102.
137. Post RM, Ballenger JC, Uhde TW, Bunney WE Jr. Efficacy of carbamazepine in manic-depressive illness: implications for underlying mechanisms. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorder. Baltimore: Williams & Wilkins; 1984. p. 777, 816.
138. Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992;12:23S-35S.
139. Kuriyama K, Kakita K. Cholera toxin induced epileptogenic focus: an animal model for studying roles of cyclic AMP in the establishment of epilepsy. In: Battistin L, editor. Neurochemistry and clinical neurology. New York: Alan R Liss; 1980. p. 141-55.
140. Ludvig N, Moshe SL. Different behavioral and electrographic effects of acoustic stimulation and dibutyryl cyclic AMP injection into the inferior colliculus in normal and in genetically epilepsy-prone rats. Epilepsy Res 1989;3:185-90.
141. Palmer GC, Jones DJ, Medina MA, Stavinoha WB. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia 1979;20:95-104.
142. Palmer GC. Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum. Exp Neurol 1979;63:322-35.
143. Elphick M, Taghavi Z, Powell T, Godfrey PP. Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948. Psychopharmacology 1990;100:522-9.
144. van Calker D, Steber R, Klotz K, Greil W. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur I Pharmacol 1991;206: 285-90.
145. Lewin E, Bleck V. Cyclic AMP accumulation in cerebral cortical slices: effect of carbamazepine, phenobarbital, and phenytoin. Epilepsia 1977;18:237-42.
146. Ferrendelli JA, Kinscherf DA. Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol 1979;5:533-8.
147. Post RM, Ballenger JC, Uhde TW, Smith C, Rubinow Dr, Bunney WE Jr. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry 1982;17: 1037-45.
148. Divish MM, Sheftel G, Boyle A, Kalasapudi VD, Papolos DF, Lachman HM. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. J Neurosci Res 1991;28:40-8.
149. Chen G, Hawver D, Wright C, Potter WZ, Manji HK. Attenuation of adenylate cyclases by carbamazepine in vitro. J Neurochemistry 1996;67:2079-86.
150. Sheng M, Greenberg ME. The regulation and function c-fos and other immediate early genes in the nervous system. Neuron 1990;4:477-85.
151. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-62.
152. Hughes P, Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 1995;47:133-78.
153. Jope RS, Song L. AP-1 and NF-κB stimulated by carbachol in human neuroblastoma SH-SY5Y cells are differentially sensitive to inhibition by lithium. Mol Brain Res 1997;50 171-80.
154. Ozaki N, Chuang D-M. Effect of lithium on transcription factor binding in cultured cerebellar granule cells and the brain of rats. J Neurochemistry 1997;69:2336-44.
155. Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997;17:12-7.
156. Williams MB, Jope RS. Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Psychopharmacology 1995;122:363-8.
157. Chen G, Yuan P, Hawver D, Potter WZ, Manji HK. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997;16:238-45.
158. Yuan PX, Chen G, Manji HK. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol Brain Res 1998;58:225-30.
159. Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK. Valproate robustly enhances AP-1 mediated gene expression. Mol Brain Res 1999;64:52-8.
160. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996;67: 443-61.
161. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-7.
162. Ketter TA, George MS, Kimbrell TA, Willis MW, Benson BE, Post RM. Neuroanatomical models and brain imaging studies. In: Joffe RT, Young LT, editors. Bipolar disorder: biological models and their clinical application. New York: Marcel Dekker; 1997. p. 179-217.
163. Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 1998;70:1768-71.
164. Lin A, Smeal T, Binetruy B, Deng T, Chambard JC, Karin M. Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res 1993;28:255-60.
165. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VMY, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997;185:82-91.
166. Stambolic V, Laurent RR, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-8.
167. Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991;64:573-84.
168. Chen G, Huang LD, Jiang YM, Manji HK. The mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase 3. J Neurochem 1999;72:1327-30.
169. Nestler EJ Antidepressant treatments in the 21st century. Biol Psychiatry 1998;44:526-33.
170. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked ? Biol Psychiatry. In press.